• About us
• Contact

Advertisement

Organisation › Details

Johnson & Johnson Innovation – JJDC, Inc.

Johnson & Johnson Innovation - JJDC, Inc (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson. *

 

	Start	2015-01-29 renamed before
	Group	Johnson & Johnson (JnJ) (Group)
	Predecessor	Johnson & Johnson Development Corporation (JJDC)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Street	410 George Street
	City	08901 New Brunswick, NJ
	Tel	+1-732-524-3218
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-07-17

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] Addex Therapeutics S.A.. (7/22/24). "Press Release: Addex’s Partner Discontinues ADX71149 Development in Epilepsy". Geneva....
• [2] Bright Peak Therapeutics AG. (6/11/24). "Press Release: Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials". Basel & San Diego, CA....
• [3] Numab Therapeutics AG. (5/28/24). "Press Release: Numab Therapeutics Announces Johnson & Johnson to Acquire Its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis". H...
• [4] Addex Therapeutics S.A.. (4/29/24). "Press Release: Addex Provides Update on ADX71149 Phase 2 Epilepsy Study". Geneva....
• [5] Basel Area Business & Innovation. (4/26/24). "Press Release: Johnson & Johnson Opens Innovation Hub in Allschwil"....
• [6] Recursion Pharmaceuticals, Inc.. (4/16/24). "Press Release: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer". Salt Lake City, UT....
• [7] Asgard Therapeutics AB. (3/14/24). "Press Release: Asgard Therapeutics Announces €30 Million Series A Financing to Advance Its First-in-Class in vivo Cell Reprogramming Platform for Immuno-oncology". Lund....
• [8] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
• [9] Nanobiotix S.A.. (7/10/23). "Press Release: Nanobiotix Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3". Paris & Cambridge, MA....
• [10] Alia Therapeutics S.r.l.. (5/5/23). "Press Release: Alia Therapeutics Names Letizia Goretti as Chief Executive Officer". Milan....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.